These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 3584272)
21. The effect of age on the pharmacokinetics of oxprenolol. Kendall MJ; Quarterman CP Int J Clin Pharmacol Ther Toxicol; 1982 Mar; 20(3):101-4. PubMed ID: 7068281 [TBL] [Abstract][Full Text] [Related]
22. Bioavailability of conventional and slow-release oxprenolol in fasted and nonfasted individuals. Dawes CP; Kendall MJ; Welling PG Br J Clin Pharmacol; 1979 Mar; 7(3):299-302. PubMed ID: 427007 [TBL] [Abstract][Full Text] [Related]
23. Relation between plasma concentrations and cardiovascular effects of oral oxprenolol in man. Brunner L; Imhof P; Jack D Eur J Clin Pharmacol; 1975; 8(1):3-9. PubMed ID: 786674 [TBL] [Abstract][Full Text] [Related]
24. The effect of food on the pharmacokinetics of nifedipine in two slow release formulations: pronounced lag-time after a high fat breakfast. Schug BS; Brendel E; Chantraine E; Wolf D; Martin W; Schall R; Blume HH Br J Clin Pharmacol; 2002 Jun; 53(6):582-8. PubMed ID: 12047482 [TBL] [Abstract][Full Text] [Related]
25. Comparison of the beta-adrenoceptor blocking activity of oxprenolol, slow release oxprenolol and a combined oxprenolol diuretic preparation. Kerr MJ; Harron DW; Kinney C; Shanks RG Br J Clin Pharmacol; 1981 Dec; 12(6):869-71. PubMed ID: 6122463 [TBL] [Abstract][Full Text] [Related]
26. The effect of oxprenolol dosage time on its pharmacokinetics and haemodynamic effects during exercise in man. Koopmans R; Oosterhuis B; Karemaker JM; Wemer J; van Boxtel CJ Eur J Clin Pharmacol; 1993; 44(2):171-6. PubMed ID: 8453962 [TBL] [Abstract][Full Text] [Related]
27. Absorption and excretion of rapid and slow release oxprenolol and their effects on heart rate and blood pressure during exercise. Bobik A; Jennings GL; Korner PI; Ashley P; Jackman G Br J Clin Pharmacol; 1979 Jun; 7(6):545-9. PubMed ID: 465276 [TBL] [Abstract][Full Text] [Related]
28. Comparison of the duration of action of pindolol and slow release oxprenolol in healthy volunteers. Aellig WH Eur J Clin Pharmacol; 1978 Nov; 14(3):167-9. PubMed ID: 729611 [TBL] [Abstract][Full Text] [Related]
30. Disposition of oxprenolol in spontaneously hypertensive rats as determined by an enzyme immunoassay. Kawashima K J Pharmacobiodyn; 1981 Jul; 4(7):534-40. PubMed ID: 7028945 [TBL] [Abstract][Full Text] [Related]
31. Relationship between systemic drug absorption and gastrointestinal transit after the simultaneous oral administration of carbamazepine as a controlled-release system and as a suspension of 15N-labelled drug to healthy volunteers. Wilding IR; Davis SS; Hardy JG; Robertson CS; John VA; Powell ML; Leal M; Lloyd P; Walker SM Br J Clin Pharmacol; 1991 Nov; 32(5):573-9. PubMed ID: 1954073 [TBL] [Abstract][Full Text] [Related]
32. Monitoring of the plasma concentration of a beta blocker with retarded effect (Slow Trasicor, 160 mg) in humans. Faragó E; Mihóczy L Int J Clin Pharmacol Ther Toxicol; 1983 Jul; 21(7):346-9. PubMed ID: 6885205 [TBL] [Abstract][Full Text] [Related]
33. Twenty-four hour effects of oxprenolol Oros and atenolol on heart rate, blood pressure, exercise tolerance and perceived exertion. van Baak MA; Verstappen FT; Oosterhuis B Eur J Clin Pharmacol; 1986; 30(4):399-406. PubMed ID: 3743615 [TBL] [Abstract][Full Text] [Related]
34. Oxprenolol: clinical pharmacology, pharmacokinetics, and pharmacodynamics. Kendall MJ; John VA Am J Cardiol; 1983 Nov; 52(9):27D-33D. PubMed ID: 6356863 [TBL] [Abstract][Full Text] [Related]
35. Osmotically controlled-delivery of metoprolol in man: in vivo performance of Oros systems with different durations of drug release. Godbillon J; Gerardin A; Richard J; Leroy D; Moppert J Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):213S-218S. PubMed ID: 4005125 [TBL] [Abstract][Full Text] [Related]
36. Osmotic delivery systems for the beta-adrenoceptor antagonists metoprolol and oxprenolol: design and evaluation of systems for once-daily administration. Theeuwes F; Swanson DR; Guittard G; Ayer A; Khanna S Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):69S-76S. PubMed ID: 4005132 [TBL] [Abstract][Full Text] [Related]
37. Relative bioavailability of oral sustained-release and regular-release oxprenolol tablets at steady-state. Gupta PK; Lim JK; Zoest AR; Lam FC; Hung CT Biopharm Drug Dispos; 1991 Oct; 12(7):493-503. PubMed ID: 1932612 [TBL] [Abstract][Full Text] [Related]
38. Preliminary study on the absorption profile after rectal and oral administration of methadone in human volunteers. Moolenaar F; Fiets G; Visser J; Meijer DK Pharm Weekbl Sci; 1984 Dec; 6(6):237-40. PubMed ID: 6549062 [TBL] [Abstract][Full Text] [Related]
39. Rectal versus oral absorption of codeine phosphate in man. Moolenaar F; Grasmeijer G; Visser J; Meijer DK Biopharm Drug Dispos; 1983; 4(2):195-9. PubMed ID: 6683976 [TBL] [Abstract][Full Text] [Related]